Table 4. Univariate and multivariate Cox regression analysis.
| Univariate Analysis | Multivariate Analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| PFS* | OS** | PFS* | OS** | |||||
| Hazard Ratio (95,0%CI) | p-value | Hazard Ratio (95,0%CI) | p-value | Hazard Ratio (95,0%CI) | p-value | Hazard Ratio (95,0%CI) | p-value | |
| CellSearch at baseline (≥5 vs <5 CTCs) | 2,4 (1,4–4,1) | 0,001 | 3,4 (1,8–6,3) | <0,001 | 1,9 (0,7–3,6) | 0,032 | - | - |
| CellSearch post 1st cycle (≥5 vs <5 CTCs) | 1,9 (1–3,5) | 0,05 | - | - | - | - | - | - |
| CellSearch on disease progression (≥5 vs <5 CTCs) | - | - | 2,1 (1,1–4,0) | 0,033 | - | - | 2,1 (1,0–4,5) | 0,043 |
| CK+/Ki67+ vs CK+/Ki67- at baseline | 2,2 (1,4–3,4) | 0,001 | 2,2 (1,4–3,7) | 0,002 | - | - | - | - |
| CK+/Ki67+ vs CK+/Ki67- post 1st cycle | 1,7 (1,1–2,8) | 0,034 | - | - | - | - | - | - |
| CK+/M30- vs CK+/M30+ at baseline | 2,4 (1,3–3,2) | 0,001 | 2,7 (1,5–4,8) | 0,001 | - | - | - | - |
| CK+/M30- vs CK+/M30+ post 1st cycle | 1,9 (1,2–3,3) | 0,012 | 4,3 (1,7–10,9) | 0,002 | - | - | - | - |
| CK+/M30- vs CK+/ M30+ on disease progression | - | - | 3,0 (1,3–6,9) | 0,013 | - | - | 6,4 (1,6–25,8) | 0,009 |
| CK+/Vim+ vs CK+/Vim- at baseline | 2,1 (1,3–3,2) | 0,001 | 2,1 (1,3–3,5) | 0,003 | - | - | 4,6 (1,2–16,8) | 0,023 |
| CK+/Vim+ vs CK+/Vim- post 1st cycle | 1,7 (1,1–2,9) | 0,032 | - | - | - | - | - | - |
Univariate and multivariate progression free survival (PFS) and overall survival (OS) analysis of small cell lung cancer patients by Cox proportional hazards model.
*PFS: Progression-free survival
**OS: Overall survival